Mingyan Jiang

Prof. Mingyan Jiang


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Pharmaceutical Biology
Verified
Journal Article
Closed access
YCYang Chu
Yang Chu
YLYifan Luo
Yifan Luo
LQLianyue Qu
Lianyue Qu
CZChunyang Zhao
Chunyang Zhao
MJMingyan Jiang
Mingyan Jiang
Context: Augmented renal clearance (ARC) refers to enhanced renal elimination of circulating solute, and has attracted wide attention in recent years. Objective: This study evaluates the effects of ARC on serum vancomycin concentration in patients administered vancomycin. Materials and methods: This was a retrospective study in patients receiving vancomycin treatment at a dose of 1000 mg in every 12 h and undergoing serum monitoring admitted over a 2-year period (May 2013 to May 2015), in order to estimate the influence of ARC on serum vancomycin concentration. In this study, statistical comparisons were made on the results from patients grouped according to creatinine clearance (CLcr). Results: One hundred forty-eight patients were enrolled in our study. The results showed that ARC patients were significantly younger, with a significantly lower Scr and higher GFR. The CLcr and steady-state trough concentrations of serum vancomycin exhibited a logarithmic correlation (Rs = −0.699, R2 = 0.488, p < 0.01) in the patients included in our study. The trough vancomycin concentrations of 62.9% patients in high CLcr group were under 10 μg/mL. Discussion and conclusion: Since ARC was significantly associated with subtherapeutic serum vancomycin concentration, it was necessary to devise adjusted dosage regimens for these patients based on their CLcr.

21 February 2014 in Molecules
Verified
Journal Article
Open access
PDF file
CYChu Yang
Chu Yang
DLDan Li
Dan Li
YLYi-Fan Luo
Yi-Fan Luo
XHXiao-Jin He
Xiao-Jin He
MJMingyan Jiang
Mingyan Jiang
Curcumin, a phenolic antioxidant compound derived from the rhizome of the turmeric plant Curcuma longa, has proven to be a modulator of intracellular signaling pathways that control cancer cell growth, inflammation, invasion and apoptosis, revealing its anticancer potential. In this study, a Glycyrrhetinic Acid-Modified Curcumin-Loaded Nanostructured Lipid Carrier (Cur-GA-PEG-NLC) was prepared by the film ultrasound method to improve the tumor-targeting ability. The drug content was detected by an UV spectrophotometry method. The encapsulation efficiency of curcumin in the nanostructured lipid carriers (NLCs) was determined using a mini-column centrifugation method. The encapsulation efficiency for various Cur-GA-PEG-NLC was within the range of 90.06%–95.31% and particle size was between 123.1 nm and 132.7 nm. An in vitro MTT assay showed that Cur-GA10%-PEG-NLC had significantly high cellular uptake and cytotoxicity against HepG2 cells compared with other groups.

1 January 2020 in Journal of Infection and Public Health
Verified
Journal Article
Open access
CYChu Yang
Chu Yang
YLYifan Luo
Yifan Luo
SJShuangmin Ji
Shuangmin Ji
MJMingyan Jiang
Mingyan Jiang
BZBaosen Zhou
Baosen Zhou
Augmented renal clearance (ARC) refers to enhanced renal elimination of circulating solute has attracted attention widely and in recent years increasing attention has been paid to patients with ARC. A population pharmacokinetic (PPK) analysis was performed to provide a reference for clinical individual therapy of vancomycin in in ARC patients. Patients hospitalized in the First Affiliated Hospital of China Medical University from July 2013 to December 2015 and suspected or confirmed infection caused by gram-positive bacteria were enrolled in this study. The serum concentrations were determined by enzyme multiplied immunoassay technique. A nonlinear mixed effects model (NONMEM) was used to evaluate the influence of covariates on vancomycin pharmacokinetics and obtain the PPK model. Bootstrap, visual predictive checks and normalized prediction distribution errors were used to evaluate the estabolishe model. A total of 186 vancomycin serum samples from 95 patients, including 24 females and 71 males were studied. The final model was as follows: [Formula: see text] and [Formula: see text] . The final PPK model in ARC patients was proved to be robust and reliable. Age was identified as the most significant covariate in the final model. In this study, a simple population pharmacokinetic (PPK) model of vancomycin in Chinese patients with ARC was established using a nonlinear mixed-effects model (NONMEM). The final PPK model could achieve a good predictive effect, which provides a reference for clinical individual therapy.

1 April 2020 in Journal of Infection and Public Health
Verified
Journal Article
Open access
CYChu Yang
Chu Yang
YLYifan Luo
Yifan Luo
XQXiaowei Quan
Xiaowei Quan
MJMingyan Jiang
Mingyan Jiang
BZBaosen Zhou
Baosen Zhou
The clinical use of intermittent infusion of vancomycin (IIV) and continuous infusion of vancomycin (CIV) is controversial. The aim of this study was to assess the effectiveness and safety of IIV and CIV by using a meta-analysis for cohort studies and randomized controlled trials. We compared the probabilities of target attainment (PTA) for the measured concentration (Cm) ≥the target concentration (Ct), the PTA for the area under the drug concentration curve/minimal inhibitory concentration (AUC/MIC) ≥400, the duration of treatment, nephrotoxicity, and overall mortality after vancomycin treatment as reported in PubMed, Embase, Cochrane, and Web of Science. A total of 14 studies with 1640 patients were included in the meta-analysis. For IIV, the PTA of Cm≥Ct (RR=0.72, 95% CI=0.60-0.88), and nephrotoxicity (RR=1.70, 95% CI=1.34-2.14) were significantly different from those of CIV. The treatment duration (SMD=0.08, 95% CI=-0.08-0.25), the PTA of AUC/MIC ≥ 400 (RR=0.84, 95% CI=0.70-1.00) and mortality (RR=0.94, 95% CI=0.72-1.25) were not significantly different from those of CIV. The results showed that CIV was easier to achieve Ct and safer than IIV. Additional randomized controlled trials focusing on the concentration of vancomycin are needed for further analysis.

13 May 2015 in Drug Research
Verified
Journal Article
Closed access
PDF file
CYC. Yang
C. Yang
LYL. Yifan
L. Yifan
LDL. Dan
L. Dan
YQY. Qian
Y. Qian
MJMingyan Jiang
Mingyan Jiang
At present, most of the lipid-lowering drugs are western medicines, which have a lot of adverse reactions. Zhucha, an age-old Uyghur medicine, is made up of bamboo leaves and tea (green tea), which has good efficacy and lipid-lowering effect. The purpose of this study was to undertake a pharmacodynamic examination of the optimal proportions of bamboo leaf flavones and tea polyphenols required to achieve lipid lowering in rats. A hyperlipidemia rat model was used to examine the lipid lowering effects of bamboo leaf flavones and tea polyphenols. Wistar rats were divided into 13 groups including one hyperlipidemia model group and 2 positive drug groups as well as experimental groups (9 groups dosed with different proportions of bamboo leaf flavones and tea polyphenols, the 3 dosages of bamboo leaf flavones were 75 mg/kg/d, 50 mg/kg/d and 25 mg/kg/d respectively, the 3 dosages of tea polyphenol were 750 mg/kg/d, 500 mg/kg/d and 250 mg/kg/d). The weight, the levels of triglyceride (TG) and high-density lipoprotein cholesterol (HDL) were determined. A high dose of bamboo leaf flavones (75 mg/kg/d) combined with a medium dose of tea polyphenols (500 mg/kg/d) was deemed to be optimal for achieving a lipid-lowering effect, the weight had the smallest increase and the level of TG and HDL was similar to positive control. The bamboo leaf flavones and tea polyphenols were mixed according to a certain proportion (1:6.7), and the mixture achieved a lipid-lowering effect and might prove to be useful as a natural lipid-lowering agent.

10 March 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
WYWenhan Yang
Wenhan Yang
PMPeng Men
Peng Men
HXHuimin Xue
Huimin Xue
MJMingyan Jiang
Mingyan Jiang
QLQiuhua Luo
Qiuhua Luo
Background: The combination of immune checkpoint inhibitors (ICIs) and chemotherapy can improve clinical outcomes in the treatment of various tumors, but may also be associated with more adverse events (AEs). We performed a systematic review and meta-analysis to characterize the risk of gastrointestinal AEs in cancer patients treated with ICI plus chemotherapy. Methods: This review was based on comprehensive search through PubMed, EMBASE, and the Cochrane Library for randomized controlled trials (RCTs) that reported gastrointestinal AEs following the use of ICI plus chemotherapy. Literature screening, data extraction, and quality evaluation were performed by two individual reviewers. Revman (version 5.3) was used for meta-analysis. Risk ratios (RR) with 95% confidence interval (CI) were calculated. Meta-analysis was conducted according to different types of ICIs [programmed death 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors]. Results: After a full-text review, 10 trials involving 5,142 patients were included in the study. Compared with chemotherapy alone, PD-1 inhibitor plus chemotherapy significantly increased the risk of diarrhea (RR = 1.38, 95% CI, 1.13–1.68, P = 0.001; I2 = 0%) and colitis (RR = 2.90, 95% CI, 1.02–8.21, P = 0.050; I2 = 0%), PD-L1 inhibitor plus chemotherapy significantly increased the risk of nausea (RR = 1.17, 95% CI, 1.02-1.35, P = 0.020; I2 = 0%), while CTLA-4 inhibitor plus chemotherapy significantly increased the risk of decreased appetite (RR = 1.49, 95% CI, 1.17–1.90, P = 0.001; I2 = 0%), diarrhea (RR = 2.23, 95% CI, 1.90–2.63, P < 0.00001; I2 = 0%), and colitis (RR = 28.39, 95% CI, 5.59–144.24, P < 0.001; I2 = 0%). Conclusions: This meta-analysis demonstrated that ICI plus chemotherapy is associated with a higher risk of gastrointestinal AEs. However, combining different ICIs may lead to diverse gastrointestinal toxicities. Clinicians should be aware of these AEs in the application of ICI plus chemotherapy.